FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 273 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR 2-Time Cancer Survivor Warns Against Breast Implants After 4 Doctors Missed... June 25, 2019 Female Breast Cancer is Now the Most Commonly Diagnosed Cancer in... February 11, 2021 Navigating Life During and After Cancer As a Young Adult: A... November 29, 2022 When You and Your Child Have VHL: 8 Ways to Cope August 11, 2020 Load more HOT NEWS Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab... How Some Brain Tumors Hijack the Mind to Grow FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced... 12 myths about sun safety debunked
